Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297697 · ClinicalTrials.gov registry record
Minimal Residual Disease in Peripheral T-cell Lymphoma
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 44
- Enrollment target
NCT03297697: Completed study, sponsored by Washington University School of Medicine.
NCT03297697 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03297697 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral T-cell lymphomas which is being given for curative intent. Additionally, as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in T-cell lymphomas.
Interventions
- PROCEDURE Tumor biopsy
- PROCEDURE Peripheral blood draw
- PROCEDURE Lymphotrack TCR clonality assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-07-31 |
| Est. Completion | 2023-11-30 |
What the finished NCT03297697 record still lists
NCT03297697 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Tumor biopsy is the first listed.
NCT03297697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03297697 about?
NCT03297697 is a clinical study titled "Minimal Residual Disease in Peripheral T-cell Lymphoma". As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral T-cell lymphomas which i...
What is the current status of trial NCT03297697?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2017-07-31. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT03297697?
The interventions under investigation include: Tumor biopsy (PROCEDURE), Peripheral blood draw (PROCEDURE), Lymphotrack TCR clonality assay (PROCEDURE).
Who is sponsoring clinical trial NCT03297697?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI